Cancer Therapeutic Procedure

Takeda and Innovent Forge $1.2B Upfront Oncology Pact for Bispecific and ADC Therapies, Total Deal Valued Up to $11.4B

5 days ago talkbio0Tagged Antibodies, Bispecific, Antibody-Drug Conjugates, Cancer Therapeutic Procedure, co-development, global strategic partnership, IBI343, IBI363, Innovent Biologics, Neoplasms, Payments, Takeda

Takeda; Innovent Biologics; global strategic partnership; bispecific antibody; antibody-drug conjugate (ADC); oncology; IBI363; IBI343; IBI3001; $1.2 billion upfront; $11.4 billion total deal; cancer therapy; co-development; milestone payments

Boehringer Ingelheim Strikes Nearly $1B ADC Deal with AimedBio; EyePoint Pharmaceuticals Announces $150M Stock Sale

2 weeks ago talkbio0Tagged AimedBio, Antibody-Drug Conjugates, Biopharma, Boehringer Ingelheim, Cancer Therapeutic Procedure, EyePoint, Funding, Licensing, stock sale, therapeutic autologous dendritic cells

Boehringer Ingelheim; AimedBio; antibody-drug conjugate; ADC; cancer therapy; biotech licensing deal; EyePoint Pharmaceuticals; stock sale; biopharma funding

Glenmark Pharma Signs $1.1 Billion Deal with Hengrui for HER2-Targeted Antibody-Drug Conjugate

1 month ago talkbio0Tagged Cancer Therapeutic Procedure, Glenmark, Hengrui Pharma, HER2-targeting antibody drug conjugate, License, milestone payments, Neoplasms, royalties, Trastuzumab Rezetecan

Glenmark; Hengrui Pharma; Trastuzumab Rezetecan; HER2-targeting antibody drug conjugate; oncology; exclusive license; $1.1 billion deal; cancer therapy; milestone payments; royalties

Nucleus RadioPharma Appoints Former FDA Commissioner Dr. Stephen Hahn as CEO

2 months ago talkbio0Tagged Appointments, biotech leadership, Cancer Therapeutic Procedure, CEO, Commissioner, Hahn, Nucleus RadioPharma, Radiopharmaceuticals, supply chain, United States Food and Drug Administration

Nucleus RadioPharma; Stephen Hahn; FDA Commissioner; CEO appointment; radiopharmaceuticals; cancer therapy; supply chain; biotech leadership

Bayer Expands Oncology Pipeline with $1.3B Kumquat Deal

3 months ago talkbio0Tagged Approved, Bayer, Cancer Therapeutic Procedure, commercialization, G12D inhibitor, K-ras Oncogene, Kumquat Biosciences, milestone payments, Oncology Pipeline, precision oncology, United States Food and Drug Administration

Bayer; Kumquat Biosciences; oncology pipeline; KRAS G12D inhibitor; FDA approval; cancer therapy; precision oncology; commercialization; milestone payments

Replimune Awaits FDA Direction After Complete Response Letter for Advanced Melanoma Therapy

3 months ago talkbio0Tagged Accelerated, Advanced Melanoma, Approved, Cancer Therapeutic Procedure, Complete, IGNYTE trial, nivolumab, Replimune, Response Letter, RETINITIS PIGMENTOSA 1, United States Food and Drug Administration, vusolimogene oderparepvec

Replimune; FDA; Complete Response Letter; RP1; vusolimogene oderparepvec; nivolumab; advanced melanoma; cancer treatment; IGNYTE trial; accelerated approval

ARTBIO Raises $132M Series B to Advance Alpha Radiotherapy Pipeline and Manufacturing with Pb212

3 months ago talkbio0Tagged AB001, alpha radioligand therapies, AlphaDirect technology, ARTBIO, Cancer Therapeutic Procedure, Clinical Trials, expansion, Manufacturing, Metastatic castration-resistant prostate cancer, PB212, Series B financing

ARTBIO; Series B financing; alpha radioligand therapies; Pb212; AlphaDirect technology; cancer treatment; manufacturing expansion; AB001; metastatic castration-resistant prostate cancer; clinical trials

Dispatch Bio Launches with $216M and CAR-T Pioneer Carl June to Advance Universal Solid Tumor Immunotherapy

3 months ago talkbio0Tagged Arch of foot, Cancer Therapeutic Procedure, CAR-T, Carl June, Dispatch Bio, Flare platform, Funding, Immunotherapy, Parker Institute for Cancer Immunotherapy, Partner in relationship, Series, Solid Neoplasm, venture

Dispatch Bio; solid tumors; immunotherapy; CAR-T; Carl June; Series A funding; Flare platform; Parker Institute for Cancer Immunotherapy; ARCH Venture Partners; universal cancer treatment